Cyclical WFE downturn + ~33% China revenue exposed to export controls, into a 66× trailing multiple
One-line thesis. KLA owns a near-monopoly in semiconductor process control (defect inspection + metrology) with 61% gross margins and ~89% ROE — a genuinely elite business — but after a +162% 12-month run the stock trades at 66× trailing / 46× forward earnings into an elevated wafer-fab-equipment (WFE) cycle, so the quality is real and the price is not obviously left on the table. Watch.
◆ Synthos call — HoldKLAC is a solid business largely reflected at ~$205 — fine to keep, no reason to chase; it gets interesting again below ~$174.
Downside Risk (lower = safer)
6/10 · High
Fortress balance sheet (net debt/EBITDA 0.7×) but 66× trailing, beta 1.50, cyclical WFE, ~33% China revenue.
Elite compounder but late-cycle and $308B cap; growth is lumpy/cyclical, not accelerating from here.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 42%/yrTo justify today’s $236, earnings would have to compound roughly 42% a year for 10 years (9% discount rate). Analysts forecast ~-16%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
KLA makes the inspection machines that check computer chips for tiny defects while they're being manufactured. Almost every advanced chip factory in the world — TSMC, Samsung, Intel — uses KLA's tools, and it has very little real competition in this niche. That's why the company is so profitable: it keeps about 33 cents of every sales dollar as profit and earns huge returns on the money it invests.
The problem is the stock price. It has more than doubled in the last year, and today you'd be paying about 66 dollars for every 1 dollar of last year's earnings — a very rich price. The chip-equipment business also goes in boom-and-bust cycles, and right now it looks like a boom. That combination — great company, high price, near a possible peak — is why our verdict is Watch: worth knowing well and buying on a pullback, not chasing here.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit above middle). The company itself is financially very strong, but the stock is expensive, jumpy (it fell 11.5% in a single day), tied to a cyclical industry, and about a third of sales go to China.
Growth Quality 8/10 (very good). A dominant, extremely profitable business that should keep growing at a healthy clip.
Exponential Potential 4/10 (below middle). It's already huge, and its growth comes in cyclical waves rather than a steady acceleration, so don't expect it to multiply quickly from here.
The one big worry: the chip-equipment cycle turns down and China demand gets cut by export rules — right when you've paid a premium price.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago
Solid = KLAC · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$235.55
Market cap$308B
P/E trailing10×
P/E FY26E / FY27E64× / 46×
EV / Sales23.8×
EV / EBITDA51.5×
Gross margin61.4%
Net margin35.7%
Dividend yield0.34%
Beta1.504
52-wk range$84 – $302
RSI(14)49
50 / 200-DMA$209 / $152
12-mo return+162% (SPY +21%)
Street target$209 ($145–$325)
Analyst grades28 Buy · 14 Hold · 2 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on KLAC · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
KLA Corporation (NASDAQ: KLAC), founded 1975 and headquartered in Milpitas, CA, is the dominant supplier of process control and yield-management systems for semiconductor manufacturing. Its tools — wafer and reticle defect inspection, metrology (measurement), and the software layer around them — sit inside chip fabs to catch defects and tune yields as feature sizes shrink. The harder chips get to make (EUV, advanced packaging, gate-all-around, HBM for AI), the more inspection and metrology intensity rises — the structural tailwind behind KLA. Fiscal year ends June 30.
The business runs in four segments: Semiconductor Process Control (the core), Specialty Semiconductor Process, PCB/Display/Component Inspection, and Other. CEO Richard Wallace; ~15,000 employees.
Revenue mix (FY2025 ended 2025-06-30, from filings):
By product line: Defect Inspection $6.20B (51%) · Service $2.68B (22%) · Patterning $2.20B (18%) · Specialty Semiconductor Process $517M · PCB & Component Inspection $356M · Other $205M. The Service line is the quality tell — a large, recurring, installed-base annuity that dampens the cyclicality of the tool sales.
By geography: China $4.04B (33%) · Taiwan $3.21B (26%) · Korea $1.45B (12%) · North America $1.36B (11%) · Japan $1.13B (9%) · Europe/Israel $574M · Rest of Asia $386M. The revenue base is Asia- and China-concentrated, which is both where leading-edge fab capex lives and the source of the single biggest structural risk (export controls — §11).
2. The expert thesis — (no expert coverage)
There is no expert coverage of KLAC in the Synthos knowledge base: total_claims = 0, 0 net-bullish voices, 0 traceable claims. Unlike our conviction-track names (e.g. LLY, 251 reconciled claims), this note carries no distilled expert thesis and cites no claim_ids, because none exist for this ticker. The verdict below is therefore fundamentals- and quant-driven only — built from FMP financials, analyst estimates, the price-target/grade consensus, and the technical block. We flag this plainly rather than manufacture conviction: absence of KB coverage is not a negative signal, but it means the usual independent-expert cross-check is unavailable here, and the call should be weighted accordingly.
The Street, for the record, is constructive: 28 Buy · 14 Hold · 2 Sell ("Buy" consensus), but the consensus price target of $209 sits below the current $235.55 — the analysts like the company more than the price, which is consistent with our own read.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Moderate-High
Balance sheet is a fortress (net-debt/EBITDA 0.7×, current ratio 3.0, interest cover 19×) — but 66× trailing / 46× FY27E, beta 1.50, a −11.5% single-day drop, cyclical WFE demand, and ~33% China revenue push risk above midpoint.
Growth Quality
8 · High
~15% forward revenue CAGR, ~20% forward EPS CAGR, 61% gross margin, ~89% ROE / 36% ROIC, a recurring service annuity, and a near-monopoly moat. Docked from 9 only by cyclicality.
Exponential Potential
4 · Moderate-Low
Real secular tailwind (inspection intensity rising with AI/advanced nodes), but growth is lumpy and cyclical, not accelerating, and a $308B cap limits the multibagger. A small accelerating name with these margins would score 8+.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. (All EPS figures are split-adjusted to match the current ~$235 share price.)
Case
Key assumptions
Fair value
Bull
AI-driven WFE stays in an extended up-cycle; leading-edge + advanced-packaging inspection intensity keeps rising; China holds. FY27E EPS beats to ~$5.60 (vs $5.13 cons) and the market pays a premium ~52× for scarce process-control exposure.
~$290 (+23%)
Base(our anchor)
Estimates roughly hit — FY27E EPS $5.13, FY28E $6.23; a durable ~20% compounder with a monopoly moat earns a ~35× forward multiple, blended across FY27–28.
~$205 (−13%)
Bear
WFE rolls over (classic semicap cycle) and/or China export controls bite; FY27E EPS misses toward ~$4.60 and the multiple de-rates to ~29× as the cycle-peak premium unwinds.
~$135 (−43%)
Synthos fair value = the base case, ~$205 (−13%), with the full $135–$290 span as the honest range. Our base sits essentially on top of the Street's $209 consensus (both below spot) — we and the analysts agree the business is excellent but the current print has run ahead of it. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). KLAC is an elite compounder, but a late-cycle one — not an exponential from today's level:
Forward growth: revenue CAGR FY25→FY30E ~15.4% ($12.16B → $24.85B); EPS CAGR ~20.2% ($3.04 → $7.63) as the mix tilts to higher-margin leading-edge and service.
Acceleration (the 2nd derivative) is cyclical, not cleanly positive: modeled revenue growth is +11% (FY26E) → +27% (FY27E) → +17% (FY28E) → +10% (FY29E) → +13% (FY30E) — a lumpy WFE-driven path, not a smooth acceleration. The big FY27 step is the tell that estimates assume the next up-leg; if the cycle instead cools, the near-term growth disappoints. Per our flagship philosophy we prize forward, accelerating names — KLAC's growth is powerful but wave-shaped.
Room to run: the process-control TAM expands with every node shrink and every new advanced-packaging/HBM ramp (genuinely secular), but at $308B market cap a 5× implies a ~$1.5T semicap company — the law of large numbers is a real ceiling.
Reinvestment runway: disciplined capex (~$340M/yr, <3% of revenue) and heavy R&D (11% of revenue) sustain the moat while throwing off ~$3.7B FCF — the reinvestment story is intact but modest in scale.
Exponential Potential: Moderate-Low (4/10). Own it, if at all, for durable ~20% earnings compounding through cycles — not for a fast multibagger, and not at a cycle-peak entry.
Revenue: FY25 (ended Jun-2025) $12.16B, +23.9% (FY24 $9.81B; FY23 $10.50B — note the FY24 cyclical dip, the signature of a semicap name). Trailing-twelve-months revenue ~$13.2B and still climbing on the latest quarters.
Margins: gross 61.4% TTM (60.9% FY25), EBITDA ~46%, operating ~42%, net 35.7% TTM (33.4% FY25). Elite for a hardware business; the recurring service mix is a big reason.
Earnings: FY25 net income $4.06B (EPS diluted $3.04), up from $2.76B FY24. Latest quarter (Mar-26) net income $1.20B, 35% net margin.
Cash flow: FY25 operating CF $4.08B, capex only −$340M → FCF $3.74B (92% FCF/OCF conversion). Capital-light for capital equipment — a structural quality marker.
Balance sheet: total debt $6.09B, cash & ST investments $4.49B → net debt ~$4.0B, net-debt/EBITDA 0.7×, current ratio 3.0×, interest coverage 19×. Investment-grade and easily serviceable. The one caveat: book equity is thin ($4.7B) after years of buybacks, which is why ROE (~89%) and price-to-book (53×) both look extreme — read ROIC (~36%) as the cleaner quality signal.
6. Valuation — priced in or room?
There is no way to call KLAC cheap. It trades at 66× trailing EPS, 23.8× sales, and 51× EV/EBITDA — richer than its own history and well above where semicap names typically change hands mid-cycle. The bull's defense is the familiar one: EPS grows into the multiple. On live consensus the forward P/E compresses to 64× (FY26E) → 46× (FY27E) → 38× (FY28E) → 31× (FY30E) — real, but still a full multiple five years out, and that path assumes the up-cycle persists. The FMP letter rating is B (overall 3/10), with price-to-earnings and price-to-book both scored 1/10 (expensive) against ROE/ROA scored 5/5 (elite) — a clean summary of the whole story: great business, stretched price. Street targets (context): consensus $209, median $200, high $325, low $145 — the consensus sits below spot, i.e. the average analyst sees modest downside to fair value even while rating it Buy. Not a value buy; a great-business-at-a-full-cyclical-price situation. Watch.
7. Technicals (from the tech block)
Trend:up, but cracking. $235.55 sits above the 50-DMA ($208.81) and 200-DMA ($151.98), and the 50 is well above the 200 (golden-cross posture) — the primary uptrend is intact. MACD +17.1 (still positive).
Location:−21.9% off the 52-week high ($307.37) and +179% off the 52-week low ($83.22) — the max drawdown from peak is that same −22%, and the stock just fell −11.5% in a single session. A parabolic advance is digesting.
Momentum: RSI(14) 49 — neutral, neither overbought nor oversold, having cooled hard from what was almost certainly an overbought peak.
Relative strength (the tell): KLAC +162% 12-mo vs SPY +20.6% / QQQ +30.3%; +55% 3-mo vs SPY +13.7%. Enormous outperformance — which is precisely why the risk/reward at this entry is asymmetric to the downside.
Read: technicals say "great trend, bad entry." The primary uptrend still holds, but a −22% drawdown and a −11.5% day after a 162% run argue for patience — a base-building period or a test toward the rising 50-DMA (~$209, which also happens to be the Street/Synthos fair value) would be a far better risk-adjusted add than chasing here.
8. Moat & competitive position
KLA's moat is one of the widest in semiconductors: it holds an estimated 50%+ share of the process-control (inspection + metrology) market, a near-monopoly built on decades of R&D, an enormous installed base, and a recurring service annuity (~22% of revenue) that raises switching costs and smooths the cycle. As nodes shrink and advanced packaging/HBM proliferate for AI, inspection intensity rises faster than wafer volume — a structural tailwind. The vulnerabilities are macro, not competitive: the WFE cycle and China/export-control policy, not a rival taking share.
Peer set (FMP-supplied, market cap): Applied Materials $479B and Lam Research $439B are the closest WFE comps (both larger, both more deposition/etch-weighted vs KLA's inspection focus); then a broader semis basket — Intel $605B, Arm $335B, Texas Instruments $267B, Amphenol $202B, Analog Devices $184B, Qualcomm $186B, Sony $122B, Accenture $84B. Within the WFE trio KLA carries the highest margins and the richest multiple — justified by the monopoly-like process-control position, but it leaves the least room for a cyclical stumble.
9. Management, capital allocation & guidance
Capital allocation: shareholder-return-heavy and disciplined — FY25 returned ~$2.15B in buybacks and ~$0.90B in dividends (~$3.05B total, ~82% of FCF) while paying down $750M of debt. The buyback has shrunk the share count from ~1.57B (FY20) to ~1.31B — a genuine per-share tailwind, though it is also why book equity (and thus reported ROE) looks extreme.
Dividend: small but growing (~0.34% yield, ~22% payout) — a compounder's dividend, not an income play.
Insider activity: the latest Form 4s (filed 2026-07-02, transactions 2026-06-30/07-01) are routine RSU vesting and tax-withholding ("F-InKind") plus a small open-market sale by the CLO (14,392 shares at $285.30). CEO Richard Wallace and CFO Bren Higgins show tax-withholding dispositions, not discretionary dumping — normal for a vesting date, no alarming cluster in the sampled window. (Note the $278–285 transaction prices vs the $235.55 quote — the June-30 vest priced near the recent peak, before the drop.)
Guidance: KLA guides one quarter forward on its earnings calls. No management claims are ingested into the Synthos KB for this name, so we rely on FMP-captured consensus rather than a distilled management-guidance voice.
10. Catalysts & what to watch
Next earnings: 2026-07-30 (FY26 Q4; Street revenue ~$3.60B). The key lines: WFE order commentary, China revenue trend, and FY27 setup — this print frames whether the assumed FY27 acceleration is real.
The WFE cycle: leading-edge fab capex (TSMC/Samsung/Intel) and AI-driven advanced-packaging + HBM demand — the single biggest swing factor.
China / export controls: ~33% of revenue; any tightening (or loosening) of US export rules moves the model materially.
Advanced-packaging & gate-all-around ramps: rising inspection intensity is the secular bull driver — watch for management quantifying it.
Multiple: after a 162% run, valuation is a catalyst — any growth wobble against a 46× forward multiple de-rates fast.
Thesis tripwires (what would change the call): a China revenue air-pocket from export controls; two consecutive quarters of WFE order deceleration; gross margin slipping below ~59%; or a break of the 200-DMA (~$152) that ends the primary uptrend. On the upside, a durable AI-WFE up-cycle with China intact would move this toward Buy — Tactical on a pullback.
11. Key risks
Cyclicality (structural): WFE is a boom-bust market (see the FY24 revenue dip); estimates currently assume the next up-leg — if it slips, near-term growth and the multiple both compress.
Valuation / de-rating: 66× trailing / 46× forward leaves no margin for a demand or China disappointment; the −11.5% day is a preview of the gap-risk.
China / geopolitics:~33% of revenue is China-facing — the largest single-country exposure and directly in the path of US export-control policy.
Customer concentration: revenue depends on a handful of leading-edge fabs (TSMC, Samsung, Intel, memory makers); a capex pause at any one is felt immediately.
Beta / drawdown: beta 1.50 and a demonstrated −22% peak-to-trough — this is a high-amplitude name, not a defensive holding.
No independent expert cross-check: 0 KB claims — we lack the outside-voice verification we apply to conviction-track names.
12. Verdict, position sizing & monitoring
Watch. KLA is a genuinely elite business — a near-monopoly in semiconductor process control with 61% gross margins, ~36% ROIC, a recurring service annuity, and a real AI-era secular tailwind. That earns the 8/10 Growth Quality. But the stock has run +162% in twelve months to 66× trailing / 46× forward earnings, into an elevated WFE cycle, with ~33% China exposure and beta 1.50 — and both our base case (~$205) and the Street consensus ($209) sit below the current $235.55. Great company, demanding price, near a possible cyclical peak: the honest verdict is Watch, not Buy.
Sizing: if already owned, treat as a satellite ≤2–3% and avoid adding here; for new money, wait for a base or a pullback toward the ~$205–210 fair-value zone (which coincides with the rising 50-DMA) for a materially better risk/reward.
Monitoring: re-underwrite on the 2026-07-30 print (China + WFE orders) and on any break of the 200-DMA; formal re-score each earnings report. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $235.55.
Single biggest risk: a cyclical WFE downturn compounded by China export controls — into a 66× trailing multiple.
Provenance & disclosures
Traceability:0 KB claims for KLAC (breadth 0, net conviction 0). This note cites no claim_ids because none exist for this ticker; the verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation) — and here we simply have no expert claims to cite.
Data as-of: fundamentals 2026-03-31 (FY26 Q3) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates. EPS figures are split-adjusted to the current ~$235 share basis.
Note on ROE / P/B: the extreme ~89% ROE and 53× price-to-book are inflated by a thin, buyback-reduced book equity; ROIC (~36%) is the cleaner quality read.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").